WASHINGTON and CAESAREA, Israel, April 30, 2019 /PRNewswire/ — Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced that it is now a member of the Digital Therapeutics Alliance (DTA) (www.DTxAlliance.org).
Dario’s acceptance to the DTA as a new member demonstrates its commitment to the core principles of the DTA – encouraging data-driven integration and utilization of digital therapeutics across the healthcare industry, engaging patients and enabling healthcare providers to intelligently manage and expand the delivery and quality of patient care, optimizing clinical treatment pathways, enhancing patient outcomes, increasing overall healthcare value and educating patients, providers, payers, and other healthcare industry stakeholders, on the value and improved health outcomes delivered through digital therapeutics.
U.S. Senate — Implementing the 21st Century Cures Act: Making Electronic Health Information Available to Patients and Providers
The U. S. Senate Committee on Health, Education, Labor and Pensions hosts a committee hearing on health data privacy, interoperability, and patient and provider access to electronic health information. An archive of the hearing and related published testimony is available.
Participants in this hearing include:
This month, we are thrilled to welcome the following companies as DTA members:
We appreciate developing such a strong diversity of perspectives across our membership and we look forward to working with each of your teams in the coming year. Welcome aboard!
DTA continues to welcome new members. If you are interested in submitting your DTx company, health system, academic medical center, investment firm, or patient advocacy organization for membership consideration, please visit the DTA membership application.
BOSTON & OSAKA, Japan — (BUSINESS WIRE) — Akili Interactive (“Akili”), a leading digital medicine company creating prescription treatments for people living with cognitive dysfunction and brain-related conditions, and Shionogi & Co., Ltd. (“Shionogi”), a major research-driven pharmaceutical company focused in two therapeutic areas: infectious diseases, and pain/CNS disorders, today announced they have entered into a strategic partnership for the commercialization of Akili’s digital medicines, AKL-T01 and AKL-T02, in Japan and Taiwan.
Akili Interactive (“Akili”), a leading digital medicine company creating prescription treatments for people living with cognitive dysfunction and brain-related conditions, and Shionogi & Co., Ltd. (“Shionogi”), a major research-driven pharmaceutical companyfocused in two therapeutic areas: infectious diseases, and pain/CNS disorders, today announced they have entered into a strategic partnership for the commercialization of Akili’s digital medicines, AKL-T01 and AKL-T02, in Japan and Taiwan. AKL-T01 is currently under review with the U.S. Food and Drug Administration (FDA) as a potential digital treatment for children with attention-deficit/hyperactivity disorder (ADHD); AKL-T02 is currently in late stage development as a potential digital treatment for cognitive dysfunction and related symptoms in children with Autism Spectrum Disorder (ASD). The digital treatments are delivered through immersive action video game experiences.
Nicky Lineaweaver/Business Insider – Digital therapeutics has caught the eye of pharmaceutical companies as a potential balm to a host of the pharma industry’s struggles, according to MedCity News. Digital therapeutics is a category of software — typically in the form of consumer-facing mobile health apps — that replaces or complements the existing treatment of a disease.
Forbes (Greg Licholai) – Quality standards are necessary to help promote adoption of the novel class of interventions called digital therapeutics. This rapidly emerging industry needs to bring together regulators, engineers, practitioners, and companies to agree on definitions that enable innovation, according to product development and regulatory specialists.
As the digital transformation sweeps through healthcare, industry experts say that new classes of medicines and therapeutics present extremely promising opportunities.
Otsuka America, Inc., and Click Therapeutics, Inc., announce today that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder (MDD), with the intent to address unmet medical needs among this patient population and to improve outcomes.This collaboration will leverage Click’s demonstrated ability to discover and validate a software application and deploy it commercially, with Otsuka’s expertise in developing approved prescription therapies for patients with serious mental illnesses, including Otsuka’s established development and commercialization capabilities. The companies believe digital therapeutics align naturally with psychiatry and have significant potential to transform mental healthcare. Together, the companies aim to bring to market a new offering that will provide a novel treatment for patients with MDD.
In December 2018, DTA hosted an election to add two new members to the board. We are therefore pleased to announce our newest Directors:
They will be joining current board members:
PharmaTimes (Jim O’Donoghue) — The future will see the pharma industry change two things: what and how it sells. As payers become more focused on Value Based Contracts (VBCs), the days of pay-per-pill are disappearing. Drugs will remain core but they will be augmented by a portfolio of digital therapies, wrap-around services and data analytics, which providers will pay for according to overall patient outcomes. But what are Digital Therapeutics, and what do they mean for pharma firms?